VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection

Amyloid

Volumn 11, Issue 4, 2004, Pages 245-256

  Gono, Takahisa ^a   Matsuda, Masayuki ^a   Shimojima, Yasuhiro ^a   Ishii, Wataru ^a   Koyama, Jun ^a   Sakashita, Kazuo ^a   Koike, Kenichi ^a   Hoshii, Yoshinobu ^b   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b YAMAGUCHI UNIVERSITY   (Japan)

Author keywords

AL amyloidosis; Autologous peripheral blood stem cell transplantation; Cardiomyopathy; High dose melphalan; Nephrotic syndrome; VAD

Indexed keywords

ALPHA INTERFERON; COTRIMOXAZOLE; DEXAMETHASONE; DIURETIC AGENT; DOXORUBICIN; M PROTEIN; MELPHALAN; VINCRISTINE;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; EXPERIENCE; FEBRILE NEUTROPENIA; FEMALE; FLUID RETENTION; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HEALTH STATUS; HEART; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; MALE; PATIENT SELECTION; PERIPHERAL NERVE; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SYMPTOM;

ADULT; AGED; AMYLOIDOSIS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; VINCRISTINE;

EID: 12244256130     PISSN: 13506129     EISSN: None     Source Type: Journal    
DOI: 10.1080/13506120412331336907     Document Type: Article

References (28)

1. Kyle RA and Gertz MA (1995). Primary systemic amyloidosis. Clinical and laboratory features in 474 Cases. Semin Hematol 32, 45-59
2. Comenzo RL, Vosburgh E, Falk RH, Sanchorawala V, Reisinger J, Dubrey S, Dember LM, Berk JL, Akpek G, LaValley M, O'Hara C, Arkin CF, Wright DG and Skinner M (1998). Dose-intensive melphalan with blood stem-cell support for the treatment of AL amyloidosis: survival and responses in 25 patients. Blood 91, 3662-3670
3. Gertz MA, Lacy MQ, Dispenzieri A, Gastineau DA, Chen MG, Ansell SM, Inwards DJ, Micallef IN, Tefferi A and Litzow MR (2002). Stem cell transplantation for management of primary sysytemic amyloidosis. Am J Med 113, 549-555
4. Dispenzieri A, Lacy MQ, Kyle RA, Therneau TM, Larson DR, Rajkumar SV, Fonseca R, Greipp PR, Witzig TE, Lust JA and Gertz MA (2001). Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol 19, 3350-3356
5. Hoshii Y, Setoguchi M, Iwata T, Ueda J, Cui D, Kawano H, Gondo T, Takahashi M and Ishihara T (2001). Useful polyclonal antibodies against synthetic peptides corresponding to immunoglobulin light chain constant region for immunohistochemical detection of immunoglobulin light chain amyloidosis. Pathol Int 51, 264-270
6. Matsuda M, Gono T, Shimojima Y and Ikeda S (2003). Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid: J Protein Folding Disord 10, 110-116
7. Skinner M, Sanchorawala V, Falk RH, Dember LM, Seldin DC, Berk J, Finn K, Libbey CA, Quillen K, LaValley M and Wright DG (2001). AL amyloidosis: severity of illness, treatment decisions and outcome in 560 patients. 9th International Symposium on Amyloidosis. Abstracts, 96 (abstr. 4.2.1)
8. Gono T, Matsuda M, Dohi N, Hoshi K, Tada T, Sakashita K, Koike K, Aizawa M and Ikeda S (2003). Nephrotic syndrome due to primary AL amyloidosis, successfully treated with VAD and subsequent high-dose melphalan followed by autologous peripheral blood stem cell transplantation. Intern Med 42, 72-77
9. Koyama J, Ray-Sequin PA and Falk RH (2002). Prognostic significance of ultrasound myocardial tissue characterization in patients with cardiac amyloidosis. Circulation 106, 556-561
10. Comenzo RL, Vosburgh E, Simms RW, Bergethon P, Sarnacki D, Finn K, Dubrey S, Faller DV, Wright DG, Falk RH and Skinner M (1996). Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: one-year follow-up in five patients. Blood 88, 2801-2806
11. Comenzo RL and Gertz MA (2002). Autologous stem cell transplantation for primary systemic amyloidosis. Blood 99, 4276-4282
12. Comenzo RL, Sanchorawala V, Fisher C, Akpek G, Farhat M, Cerda S, Berk JL, Dember LM, Falk R, Finn K, Skinner M and Vosburgh E (1999). Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM + G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol 104, 553-559
13. Dimopoulos MA, Delasalle KB, Champlin R and Alexanian R (1993). Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma. Br J Haematol 83, 240-244
14. Sezer O, Schmid P, Schweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H and Possinger K (1999). Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support. Bone Marrow Transplant 20, 967-969
15. Moreau P, Leblond V, Bourquelot P, Facon T, Huynh A, Caillot D, Hermine O, Attal M, Hamidou M, Nedellec G, Ferrant A, Audhuy B, Bataille R, Milpied N and Harousseau J-L (1998). Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol 101, 766-769
16. Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K and Skinner M (2001). An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant 28, 637-642
17. Gono T, Matsuda M, Dohi N, Sekijima Y, Tada T, Sakashita K, Koike K, Kadosaka S and Ikeda S (2002). Gastroduodenal lesions in primary AL amyloidosis. Gastrointest Endosc 56, 563
18. Molee PN, Wechalekar AD, Pereira DL, Franke N, Reece D, Chen C and Stewart AK (2003). Autologous stem cell transplantation in primary systemic amyloidosis: the impact of selection criteria on outcome. Bone Marrow Transplant (Epub ahead of print)
19. Kumar S, Dispenzieri A, Lacy MQ, Litzow MR and Gertz MA (2001). High incidence of gastrointestinal tract bleeding after autologous stem cell transplant for primary systemic amyloidosis. Bone Marrow Transplant 28, 381-385
20. van Gameren II, Hazenberg BPC, Jager PL, Smit JW and Vellenga E (2002). AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid: J Protein Folding Disord 9, 165-174
21. Sezer O, Eucker J, Schmid P and Possinger K (2000). New therapeutic approaches in primary systemic AL amyloidosis. Ann Hematol 79, 1-6
22. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Finn KT, Dember LM, Berk JL, Quillen K, Anderson JJ, Comenzo RL and Skinner M (2003). High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant (Epub ahead of print)
23. Gillmore JD, Apperley JF, Lachmann HJ, Barrett AJ, Madhoo S, Pepys MB and Hawkins PN (2001). Combination chemotherapy for systemic AL amyloidosis. 9th International Symposium on Amyloidosis. Abstracts, 100 (abstr. 4.2.5)
24. Palladini G, Perfetti V, Obici L, Caccialanza R, Semino A, Adami F, Cavallero G, Rustichelli R, Virga G and Merlini G (2004). Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103, 2936-2938
25. Gertz MA, Lacy MQ, Gastineau DA, Inward DJ, Chen MG, Tefferi A, Kyle RA and Litzow MR (2000). Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant 26, 963-969
26. Dhodapkar MV, Jagannath S, Vesole D, Munshi N, Naucke S, Tricot G and Barlogie B (1997). Treatment of AL-amyloidosis with dexamethasone plus alpha interferon. Leuk Lymphoma 27, 351-356
27. Skinner M, Anderson J, Simms R, Falk R, Wang M, Libbey C, Jones LA and Cohen AS (1996). Treatment of 100 patients with primary AL amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med 100, 290-298
28. Sanchorawala V, Wright DG, Seldin DC, Falk RH, Berk JL, Dember LM, Finn KT and Skinner M (2002). Low-dose continuous oral melphalan for the treatment of primary systemic (AL) amyloidosis. Br J Haematol 117, 886-888